Format

Send to

Choose Destination
Blood. 2015 Jan 29;125(5):742-4. doi: 10.1182/blood-2014-12-616300.

Dissecting complement blockade for clinic use.

Author information

1
FEDERICO II UNIVERSITY.

Abstract

In this issue of Blood, Peffault de Latour et al describe ex vivo measurements of complement activity in paroxysmal nocturnal hemoglobinuria (PNH) patients on eculizumab treatment. This is the first systematic pharmacodynamic (PD) study of eculizumab in PNH patients which shows that CH50 is a promising biomarker of therapeutic complement blockade.

PMID:
25634611
DOI:
10.1182/blood-2014-12-616300
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center